Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Prometheus Biosciences, Inc. (RXDX)
|
Add to portfolio |
|
|
|
| Price: |
$38.18
| | Metrics |
| OS: |
47.8
|
M
| |
-22
|
% ROE
|
| Market cap: |
$1.83
|
B
| |
-24
|
% ROIC
|
|
Net cash:
|
$113
|
M
| |
$2.37
|
per share
|
|
EV:
|
$1.71
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($154)
|
M
| |
|
|
| EPS |
($3.48)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 3.1 | 1.2 | 11.0 |
| Revenue growth | 154.6% | -88.8% | |
| Cost of goods sold | 0.0 | 0.0 | 11.0 |
| Gross profit | 3.1 | 1.2 | 0.0 |
| Gross margin | 100.0% | 100.0% | 0.0% |
| Research and development | 62.4 | 19.1 | |
| General and administrative | 28.5 | 11.1 | 6.1 |
| EBIT | -87.8 | -29.0 | -16.0 |
| EBIT margin | -2806.1% | -2360.2% | -145.7% |
| Pre-tax income | -90.2 | -31.1 | -16.7 |
| Income taxes | 0.0 | 6.0 | 13.0 |
| Tax rate | 0.0% | | |
| Earnings from continuing ops | -90.2 | -31.1 | -29.7 |
| Earnings from discontinued ops | | -6.0 | -13.0 |
| Net income | -90.2 | -37.1 | -29.7 |
| Net margin | -2882.6% | -3021.8% | -271.2% |
| |
| Diluted EPS | ($2.88) | ($20.77) | ($26.47) |
| Shares outstanding (diluted) | 31.3 | 1.5 | 1.1 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|